Missed Opportunities on Emergency Remdesivir Use

JAMA. 2020 Jul 28;324(4):331-332. doi: 10.1001/jama.2020.11932.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Monophosphate / adverse effects
  • Adenosine Monophosphate / analogs & derivatives*
  • Adenosine Monophosphate / economics
  • Adenosine Monophosphate / supply & distribution
  • Adenosine Monophosphate / therapeutic use
  • Alanine / adverse effects
  • Alanine / analogs & derivatives*
  • Alanine / economics
  • Alanine / supply & distribution
  • Alanine / therapeutic use
  • Antiviral Agents / adverse effects
  • Antiviral Agents / economics
  • Antiviral Agents / supply & distribution
  • Antiviral Agents / therapeutic use*
  • Betacoronavirus*
  • COVID-19
  • Clinical Trials, Phase III as Topic
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / epidemiology
  • Drug Approval
  • Drug Costs
  • Drugs, Investigational / adverse effects
  • Drugs, Investigational / economics
  • Drugs, Investigational / supply & distribution
  • Drugs, Investigational / therapeutic use*
  • Hemorrhagic Fever, Ebola / drug therapy
  • Humans
  • Length of Stay
  • National Institute of Allergy and Infectious Diseases (U.S.)
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / epidemiology
  • Registries
  • SARS-CoV-2
  • Treatment Outcome
  • United States / epidemiology

Substances

  • Antiviral Agents
  • Drugs, Investigational
  • remdesivir
  • Adenosine Monophosphate
  • Alanine

Supplementary concepts

  • COVID-19 drug treatment